CHIP GmbH / Technology Center

Strategy development for the Percutaneous Isolated Hepatic Perfusion (PIHP) therapy for liver cancer

“Based on our previous experiences with SilverSky, the group was mandated to provide an independent feasibility assessment regarding the opportunity of implementation and commercialization of the Japanese PIHP chemosaturation system in Europe and particularly in the German market. The assessment was based on literature and database research to analyze background information about the application (liver cancer), the chemosaturation system, market size and potential and regulatory requirements, as well as an analysis of key competitors. In addition, Dr. Stange and Ms. Klingen confirmed the potential of the PIHP treatment and its market acceptance by interviews with key opinion leaders. The assessment concluded with final recommendation for European commercialization strategy, including potential milestones and funding requirements. In summary, overall quality and depth of analysis, as well as the timely presentation of the results, exceeded our expectations and we look forward to working with the team again.”

Dr. Bernd Rosenfeld, CEO Technologiezentrum Bochum

Milestones:

  • SilverSky engagement
  • 2014-15: Strategy developed for CHIP collaboration partner

Founded: n/a

Locations: Bochum, Germany

www.chp-gmbh.com

contact

Silversky GmbH

Brunnenstrasse 23 40223 Düsseldorf
Germany

E-Mail: info@silversky-lifesciences.com

Impressum | Datenschutz

WRITE US AN EMAIL